Key result
Increased admission HbA1c levels (≥ 6.5%) were associated with a significantly higher 1-year rate of major adverse cardiovascular events (22.4%) compared to lower HbA1c levels in patients with STEMI undergoing primary PCI.
Why the study?
Does admission HbA1c level predict in-hospital, short-, and long-term cardiovascular mortality and major adverse cardiovascular events in patients with STEMI undergoing primary PCI?
Population
443 consecutive patients with ST-segment elevation myocardial infarction undergoing primary percutaneous…
Comparison
Admission HbA1c level ≥ 6.5% or 5.7-6.4% vs Admission HbA1c level ≤ 5.6% (Group I)
Design
Cohort
Follow-up
1 year
Authors
Loading...
Supports HbA1c for risk stratification in STEMI PCI; leaves open whether targeting it improves outcomes.
Observational (n=443)
No
Does admission HbA1c level predict in-hospital, short-, and long-term cardiovascular mortality and major adverse cardiovascular events in patients with STEMI undergoing primary PCI?
Absolute Event Rate: 22.4% vs 12.6%
p-value: p=0.037
Elevated admission HbA1c is associated with increased 1-year major adverse cardiovascular events in STEMI patients undergoing primary PCI, highlighting its prognostic value for risk stratification.
Püşüroğlu et al. (2014) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=443). Admission Haemoglobin A1c (HbA1c) ≥ 6.5% vs. Admission HbA1c ≤ 6.4% was evaluated on 1-year primary clinical outcomes (composite of cardiovascular mortality, non-fatal reinfarction, and stroke) (p=0.037). Increased admission HbA1c levels (≥ 6.5%) were associated with a significantly higher 1-year rate of major adverse cardiovascular events (22.4%) compared to lower HbA1c levels in patients with STEMI undergoing primary PCI.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: